AURAAura Biosciences, Inc.
$6.50+13% 1Y
$6.50
$4.9752 weeks$8.90
AURA in its own filings
Nothing in AURA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
94
Events found in the filings · across 378 filings · the record starts in 2021
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 11, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 10, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- SEC comment-letter activity11 occurrences
- 2024-04-03
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026On the Effective Date the Company announced its organizational realignment (the “Realignment”) to streamline its operating plan and organizational structure to focus resources in ocular oncology, including its plan to minimize resource allocation towards its non-muscle invasive bladder cancer (“NMIBC”) program on a …Earnings release · Form 8-K
- Jul 8, 2026Appointment of New Director to the Board of Directors On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the …Director or officer change · Form 8-K
- May 11, 2026On May 11, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts, and others.Earnings release · Form 8-K
- May 5, 2026On May 4, 2026, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten …Material agreement entered · Form 8-K
- May 4, 2026On April 30, 2026, Aura Biosciences, Inc. (the “Company”) and Matrix Capital Management Master Fund, LP (“Matrix”) entered into a stock purchase agreement (the “Repurchase Agreement”) pursuant to which the Company has agreed to repurchase, in a privately negotiated transaction, up to 6,922,870 shares of its common …Material agreement entered · Form 8-K
- May 4, 2026Appointment of Chief Executive Officer and President On April 29, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of …Director or officer change · Form 8-K
- Mar 30, 2026On March 30, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts, and others.Earnings release · Form 8-K
- Nov 13, 2025On November 13, 2025, the Company updated its corporate presentation for use in meetings with investors, analysts, and others.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…